Business Development
Our Business Development & Licensing teams are made up of skilled professionals with precise knowledge of all the steps involved in pharmaceutical development. You can reach out to them to discuss your innovative project ideas.
What are our focus areas?
Oncology
Oncology is now a growth driver for Pierre Fabre’s pharmaceutical activities, via R&D and business partnerships with companies that have developed targeted therapies for cancer treatment (solid and hematologic tumors).
We focus on innovative products from the preclinical phase to late development phases:
- Innovative products targeting sub-populations of patients with solid tumors such as skin cancers, including melanoma, gastrointestinal cancers, lung cancers, and so on.
- Targeted therapies aimed at oncogenes or the core signaling pathways involved in tumorigenesis and resistance.
We are interested in various therapeutic classes, including small molecules, monoclonal antibodies, and antibody-drug conjugates.
Dermatology
Pierre Fabre is a leading player in the field of medical dermatology.
As part of our growth strategy, we have identified three priority therapeutic areas: onco-dermatology, rare skin diseases, and pediatric dermatology.
Our franchise examines all drug candidates that have achieved clinical proof of concept.
Rare diseases
We actively pursue partnerships to develop innovative treatments in the marketing or clinical development phase with proven efficacy in humans.
We are interested in various therapeutic classes including small molecules, monoclonal antibodies, and innovative therapy medicinal products.
Our global presence allows us to seek out partnerships in Europe, the USA, and Asia.
Dermo-cosmetics
Our priorities include acquiring rights and working with partners to develop innovative ingredients with proven clinical efficacy for our formulas.
We also channel our efforts into formulation technologies, innovative packaging options, and electronic devices for dermo-cosmetic use.
